Clinical Trial Search

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…

Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…

Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…

Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants

Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events

Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants

Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants

Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants

Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants

Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825

Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL

Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005

Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants

Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181

Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants

Primary: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus — 17; 19; 15…

Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage

Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25

Primary: Viral Shedding — 8; 4; 7; 4 Participants

Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants